4 quarters tracked · Beat rate 75% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $1.56 | $1.60 | +2.5% | Beat |
| Q4 2025 | 2025-12-31 | $2.24 | $-0.24 | -110.7% | Miss |
| Q3 2025 | 2025-09-30 | $1.66 | $1.72 | +3.6% | Beat |
| Q2 2025 | 2025-06-30 | $1.29 | $1.54 | +19.3% | Beat |
Earnings Beat Rate
Halozyme has beaten analyst EPS estimates in 3 of 4 tracked quarters (75% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →